Utah Medical Products Inc. develops, manufactures and markets disposable and reusable specialty medical devices, with a stated focus on health care for women and babies. Its products are used in areas such as blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology and urology, serving hospitals, outpatient clinics and physicians' offices.
Company updates commonly cover quarterly and annual financial performance, domestic and outside-U.S. sales trends, foreign-currency effects, product-category demand, OEM and distributor relationships, and profit margins. Recurring corporate actions include quarterly cash dividends, open-market share repurchases when disclosed, board appointments and other governance updates for the Nasdaq-listed common stock.
Summary not available.
Summary not available.
Utah Medical Products reported its 1Q 2023 financial results, showing a 1.6% increase in revenues to $12,520k compared to the same period in 2022. The gross profit rose by 4.1% to $7,843k. However, operating income fell 1.9% to $4,439k, indicating rising litigation expenses. Net income increased 19.2%, reaching $4,214k, with earnings per share up by 20.2% at $1.159. The gross profit margin improved to 62.6% from 61.1%. International sales surged 22.9%, while domestic sales dropped 10%. As of March 31, 2023, cash and investments totaled $80.9 million, up from $75.1 million at year-end 2022.
Utah Medical Products, Inc. (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.295 per share, payable on April 4, 2023, to shareholders recorded by close of business on March 17, 2023. This marks a 1.7% increase compared to the same period last year. The company specializes in medical devices for women and babies, with products recognized globally for optimal patient outcomes. For more details on Utah Medical Products, Inc., visit www.utahmed.com.
Utah Medical Products reported a strong financial performance for 2022, with revenues increasing by 7% year-over-year, and net income rising by 11%. Despite a stronger USD impacting foreign currency sales, constant currency sales showed a 10% growth. Key metrics revealed a 3% increase in gross profit and earnings per share up by 12%. Operating income faced a slight decline of 1% due to higher legal costs. The company finished the year with $75.1 million in cash and investments, marking a 23% increase from 2021. Overall, UTMD has strengthened its balance sheet while dealing with inflationary pressures and supply chain challenges.
Utah Medical Products, Inc. (UTMD) announced a quarterly cash dividend of $0.295 per share, payable on January 4, 2023, to shareholders of record by December 16, 2022. This represents a 1.7% increase from the prior dividend. The company specializes in developing and marketing medical devices focused on women's health and neonatal care, with products recognized globally for optimal patient outcomes.
Utah Medical Products (Nasdaq: UTMD) reported a mixed financial performance for Q3 2022, with revenues rising 3% year-over-year, while gross profit and operating income saw modest increases of 1%. Net income rose by 2%, reflecting ongoing challenges like supply chain disruptions and litigation costs, as well as the impact of a stronger USD on foreign sales. Despite these hurdles, management highlighted better-than-expected results and maintained a solid cash position of $69.5 million, alongside a commitment to stock repurchases and dividends, indicating continued shareholder value focus.
Utah Medical Products (NASDAQ:UTMD) declares a quarterly cash dividend of $0.29 per share, payable on October 5, 2022, to shareholders on record by September 16, 2022. This dividend reflects a 1.8% increase compared to the same quarter last year. Utah Medical Products specializes in developing and manufacturing medical devices for women and infants, recognized globally for quality and performance.
UTMD reported strong financial results for Q2 and H1 2022, exceeding initial projections. Revenues grew by 7% in Q2 and 9% in H1 compared to 2021, while net income surged by 19.7% in Q2 and 18% in H1. Despite rising variable costs impacting profit margins, operating income increased by 6% in Q2 and 10.7% in H1. The company maintained a robust balance sheet with no debt, and cash and investments rose to $66.2 million. The share price ended Q2 at $85.90, reflecting a 14.1% decline from the end of 2021, partly due to external market pressures.
Utah Medical Products (NASDAQ:UTMD) has announced a quarterly cash dividend of $.29 per share, payable on July 6, 2022, to shareholders of record by June 17, 2022. This reflects a 1.8% increase over the previous year's dividend. The company focuses on developing and marketing specialty medical devices for women and their babies, recognized for optimal long-term outcomes globally.